Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2438 results about "Obesity" patented technology

A condition characterized by abnormal or excessive fat accumulation.

GLP-1R and GCGR double-target-activated polypeptide or derivative thereof, pharmaceutically acceptable salt and application of polypeptide or derivative and pharmaceutically acceptable salt

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Compound containing multi-fused ring structure

The present invention is in the field of pharmaceutical chemistry, and relates to a compound containing a multi-fused ring structure, specifically to a compound of formula (I), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, or a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating diabetes or obesity-related diseases.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Personalized diagnosis method for intestinal flora and obesity based on graph attention network

The invention discloses an intestinal flora and obesity personalized diagnosis method based on a graph attention network, and relates to the technical field of obesity diagnosis, and the method comprises the following steps: collecting gene data, building a graph structure-based model for the data to predict obesity risk and provide personalized health suggestions, each piece of microbiome data is expressed as a weighted undirected graph, a microbiome graph is constructed, the association strength between microbiome groups is calculated, and the microbiome data is expressed as a graph structure. According to the method, the graph structure model considering the relevance between the microbiome groups is constructed, the self-adaptive graph convolutional network and the heterogeneous graph attention network are utilized, multi-modal information interaction between the microbiome and clinical data is deeply mined, the processing capacity of high-dimensional and complex microbiome data is improved, and the multi-modal information interaction between the microbiome and clinical data is improved. The accurate prediction of obesity risks and the provision of personalized health suggestions are realized, the prediction accuracy and generalization ability of the model are significantly improved, and a more effective personalized obesity diagnosis effect is achieved.
Owner:SHANGHAI BAO PUZI HEALTH TECHNOLOGY CO LTD

Pharmacotherapies for improving treatment adherence after discontinuation of incretin-based therapies

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.
Owner:LUMINOUS MIND INC

Human body abdominal fat analysis method based on medical image

The invention relates to the technical field of medical image processing, and discloses a human body abdominal fat analysis method based on a medical image, which comprises the following steps: acquiring multi-modal medical image data such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and ultrasonic images, constructing a fusion database through multi-scale affine transformation alignment, de-noising by using a model based on a residual self-encoder, and enhancing a boundary in combination with Canny edge detection. A segmentation model is constructed based on an improved U-Net architecture, multi-modal features are fused, and a dynamic convolution kernel and a channel attention mechanism are used for optimization. A quantitative analysis model is established by adopting a multi-task joint learning framework, gradient conflicts are solved, and a lightweight sub-network is searched and generated. Carrying out uncertainty modeling on the segmentation model, and carrying out active learning annotation to optimize the performance. A multi-granularity feature fusion framework is designed, anatomical priori knowledge is embedded to construct an association graph, a structured analysis report is generated, abdominal fat can be accurately analyzed, and diagnosis and treatment of obesity-related diseases are assisted.
Owner:BEIJING EVERBRIGHT HONGDA TECHNOLOGY CO LTD

Imidazol-2-one derivative and use thereof in medicine

Provided in the present invention are a tetrahydropyridopyrazole derivative and use thereof in medicine. Specifically provided is a compound as shown in general formula (I) or a racemate, stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a preparation method therefor, and use thereof in the preparation of a related drug for treating diabetes or obesity.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

Chemical ablation and method of treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Owner:NEUROTRONIC INC

BMI driving type 3D organ obesity visualization system based on multi-modal fusion

The invention discloses a BMI-driven 3D organ obesity visualization system based on multi-modal fusion, and relates to the technical field of medical science, the system comprises a BMI-driven prediction model, the BMI-driven prediction model is used for establishing a quantitative mapping model of a BMI index and three-dimensional organ fat deposition, and the quantitative mapping model is used for establishing a BMI index and three-dimensional organ fat deposition. The BMI driving type prediction model comprises a multi-modal data fusion unit, a model mapping unit and a residual compensation unit. By installing the BMI driving type prediction model, precise nonlinear mapping of the BMI index and organ fat deposition is achieved, the problem that traditional single-mode prediction is large in deviation is solved, and organ fat volume prediction precision and individual difference adaptability are improved.
Owner:FOSHAN CHANCHENG CENT HOSPITAL CO LTD

Chemical ablation and method of treatment for various diseases

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B
Owner:NEUROTRONIC INC

Chemical ablation formulations and methods of treatments for various diseases

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None
Owner:NEUROTRONIC INC

Chemical ablation formulations and methods of treatments for various diseases

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.
Owner:NEUROTRONIC INC

GLP-1 receptor agonist, and preparation method therefor and use thereof

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.
Owner:GUANGZHOU UNIRISE PHARM CO LTD +3

Antibody conjugates and fusion proteins

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.
Owner:SIXPEAKS BIO AG

Application of hispidulin in preparation of lipid de novo synthesis inhibitor or metabolism-related fatty liver disease treatment or prevention product

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.
Owner:SHANGHAI SEVENTH PEOPLES HOSPITAL

Application of bifidobacterium animalis subsp. Lactis or composition in preparation of product for preventing and / or treating metabolic diseases

The invention relates to an application of a bifidobacterium animalis subsp. Lactis BGI-N3 (the preservation number is CCTCC (China Center For Type Culture Collection) NO: M20221585) or a composition containing the bifidobacterium animalis subsp. Lactis BGI-N3 as an active ingredient in the preparation of a product for preventing and / or treating metabolic diseases, and particularly relates to an application of the bifidobacterium animalis subsp. Lactis BGI-N3 or a composition containing the bifidobacterium animalis subsp. Lactis BGI-N3 as an active ingredient in the preparation of a product for preventing and / or treating metabolic diseases. The bifidobacterium animalis subsp. Lactis comprises a 16S rDNA (ribosomal deoxyribonucleic acid) sequence as shown in SEQ ID NO: 1. The animal bifidobacterium subsp. Lactis BGI-N3 provided by the embodiment of the invention has good safety and excellent gastrointestinal tract environment tolerance, and can effectively reduce the food calorie conversion rate, regulate the systemic chronic inflammation level and improve the fat accumulation condition so as to prevent and / or treat metabolic diseases, such as obesity.
Owner:BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO LTD

GLP-1-fc-FGF21 double-target fusion protein composition, and injection and use thereof

A GLP-1-Fc-FGF21 double-target fusion protein composition and the use thereof. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by means of adding the buffer solution, the generation of visible particles can be effectively controlled, and the stability of the GLP-1-Fc-FGF21 fusion protein is improved, so that the shelf life of a product can be prolonged. The composition can be used for treating and / or preventing metabolic diseases, such as diabetes, hyperlipidemia, obesity and diseases related to fatty liver.
Owner:SUNSHINE LAKE PHARMA CO LTD

Phytobacterium plantarum PD01 and application thereof

The invention relates to the technical field of microorganisms, and particularly discloses plant lactobacillus PD01 and application thereof. The lactobacillus plantarum PD01 is preserved in the China General Microbiological Culture Collection Center on April 22, 2024, and the preservation number of the lactobacillus plantarum PD01 is CGMCC (China General Microbiological Culture Collection Center) No.30386. The lactobacillus plantarum PD01 has the advantages that the lactobacillus plantarum PD01 is preserved in the China General Microbiological Culture Collection Center on April 22, 2024; through caenorhabditis elegans and mouse models, it is proved that the plant lactobacillus PD01 reduces obesity and inflammatory reactions caused by ingestion of microplastics by preventing the microplastics from penetrating through intestinal barriers.
Owner:XIAMEN YUEYI BIOTECHNOLOGY CO LTD

Activin receptor type IIa variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Owner:KEROS THERAPEUTICS INC

Steroid compound as well as preparation method and application thereof

The invention discloses a steroid compound as well as a preparation method and application thereof. The invention specifically discloses a steroid compound with a structure as shown in a formula I and the like or a pharmaceutically acceptable salt of the steroid compound. The compound provided by the invention has SREBP pathway inhibitory activity, and can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases. # imgabs0 #
Owner:CHOLESGEN (SHANGHAI) CO LTD

Α-amylase inhibitory peptide and use thereof

PCT designated stageWO2025167858A1Metabolism disorderPeptide/protein ingredientsDiseaseAmylase inhibitors
An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.
Owner:ECOSLIM INC

Apparatus for treating obesity

ActiveUS12226331B2Stomach wallsAnatomy
An apparatus for treating obesity in a human or animal mammal patient. The apparatus comprising a first volume filling device segment and a second volume filling device segment. The first and second volume filling device segments are adapted to be assembled into an implantable volume filling device of a controlled size. Each one of the first and second volume filling device segment comprises at least one interconnecting structure. The interconnecting structure of the second volume filling device segment is adapted to be formed fitted, such that the first and second volume filling device segment can be assembled into the volume filling device. The assembled volume filling device is adapted to be at least substantially invaginated by a stomach wall portion of a patient, with the outer surface of the device resting against the stomach wall, such that the volume of the food cavity is reduced in size.
Owner:FORSELL PETER

Dosing of incretin pathway drugs

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity, the method comprising: receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and indicating the dosage.
Owner:CLOSED LOOP MEDICINE LTD

Compounds and their uses as thyroid hormone receptor agonists

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto. (I), (Ia)
Owner:NANJING RUIJIE PHARMATECH CO LTD

Child obesity early warning method and system based on obesity risk factor analysis

PendingCN121075624AMedical data miningHealth-index calculationOlder childChild obesity
The invention discloses a children obesity early warning method and system based on obesity risk factor analysis, and the method comprises the steps: carrying out the feature screening of collected children multi-dimensional health related data containing parental information, birth history and lifestyle, and recognizing the important risk factors and weights of children obesity; important risk factors are supplemented through literature review; the method comprises the following steps: formulating scale questions including parental information, birth history and lifestyle based on important risk factors and weights in combination with clinical expert opinions, assigning scores to the scale questions, dividing according to a scale score result to form children obesity risk prediction levels, and providing personalized health management schemes for subjects with different risk levels. The method is low in cost, easy to implement, high in compliance and based on non-invasive characteristics, and is particularly suitable for early obesity screening and early warning of 3-6-year-old children.
Owner:ZHEJIANG UNIV